CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.
September 6th 2018
This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.
September 3rd 2018
One of the things I think about is the future. All cancer patients know we have two futures: One where things go well, and one where they don't.
August 30th 2018
Deferring treatment may actually be beneficial for some patients with mantle cell lymphoma (MCL), according to recent research.
August 20th 2018
While the treatment landscape of mantle cell lymphoma (MCL) has continued to evolve in recent years, researchers and clinicians alike are still at a loss for curative strategies. But immunotherapy may help.
July 26th 2018
Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.
July 11th 2018
A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.
July 9th 2018
There are many exciting advances happening in the field of mantle cell lymphoma.
July 5th 2018
Since its classification in 1994, the prognosis for patients diagnosed with mantle cell lymphoma (MCL) was generally poor; however, survival rates have nearly doubled thanks to improvements in the treatment landscape over the past 10 years.
June 28th 2018
Moving from shock to action is hard, but it's critical to surviving cancer
June 25th 2018
Patients with mantle cell lymphoma (MCL) who were treated with Venclexta (venetoclax) showed a slight improvement in response rates compared with chemoimmunotherapy.
May 18th 2018
Do you know the difference between happiness and joy?
May 7th 2018
A higher complete response rate was seen in patients given both agents compared with those given Imbruvica alone.
May 6th 2018
The treatment landscape of mantle cell lymphoma is continuing to change. See what expert Andre Goy, M.D., has to say about it.
April 18th 2018
Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.
March 23rd 2018
Kevin unleashes his inner guilt for the benefit of you, gentle readers.
November 2nd 2017
You walk in and the entire staff yells your name, al la “Norm” of Cheers fame
May 15th 2017
Grzegorz S. Nowakowski, M.D., discusses the potential for genetic testing for patients with mantle cell lymphoma.
April 7th 2017
A non-runner explains why running and cancer are the same thing. Except they're not.
March 30th 2017
Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).
March 5th 2017
In this episode of Cancer With Kevin, we explore the unexpected humor that comes with the general awfulness
January 31st 2017
Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.
November 28th 2016
After two transplants and two relapses, it's time to go down a novel road.
July 27th 2016
If you've relapsed after you thought you'd been cured, you know what a shock it is. Relapsing twice, after two transplants, turns out to have a surprisingly different effect on Kevin.
June 27th 2016
Kevin compares building and fighting robots with enduring and fighting cancer-- a surprising synergy!
April 1st 2016
Life after cancer calls for yet another new normal.
December 1st 2015
Most cancer survivors are familiar with Psalm 23 and the feeling of walking through the valley of the shadow. We also need to remember that there's another side to the valley, where the light shines brightly.
November 4th 2015
The recent World Health Organization announcement classifying processed meat as a Group 1 carcinogen isn't really news. It's just common sense.